Please sign in to follow a disease.
Relapsed or refractory peripheral T-cell lymphoma
Clinical trials for Relapsed or refractory peripheral T-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed or refractory peripheral T-cell lymphoma trials appear
Sign up with your email to follow new studies for Relapsed or refractory peripheral T-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a drug duo outsmart resistant T-Cell lymphoma?
Disease control CompletedThis phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults wit…
Matched conditions: RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase 2 • Sponsor: John Reneau • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called XNW5004 in 120 people with advanced tumors or lymphoma that had come back or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it helps shrink tumors. The drug is taken as a tabl…
Matched conditions: RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC